Amneal Pharmaceuticals, Inc.
AMRX
$12.60
-$0.18-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.62% | 8.05% | 9.50% | 9.81% | 13.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.62% | 8.05% | 9.50% | 9.81% | 13.42% |
| Cost of Revenue | 3.03% | 6.23% | 8.22% | 7.92% | 13.70% |
| Gross Profit | 15.63% | 11.22% | 11.71% | 13.13% | 12.94% |
| SG&A Expenses | 13.52% | 10.56% | 11.47% | 8.64% | 9.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 96.45% | -5,340.00% | -7,541.43% | -3,060.69% | -2,853.76% |
| Total Operating Expenses | 4.77% | 6.19% | 8.97% | 9.04% | 12.82% |
| Operating Income | 26.98% | 21.12% | 13.11% | 15.12% | 17.73% |
| Income Before Tax | 213.65% | 353.05% | 155.75% | 177.24% | 154.52% |
| Income Tax Expenses | -97.72% | -40.22% | -52.68% | 116.47% | 83.46% |
| Earnings from Continuing Operations | 459.27% | 273.17% | 139.34% | 138.47% | 126.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.19% | -29.91% | -36.19% | -15.58% | 6.03% |
| Net Income | 1,035.91% | 161.65% | 103.20% | 101.93% | 92.27% |
| EBIT | 26.98% | 21.12% | 13.11% | 15.12% | 17.73% |
| EBITDA | 10.56% | 10.41% | 10.24% | 12.60% | 12.84% |
| EPS Basic | 1,018.25% | 160.51% | 102.62% | 101.59% | 92.50% |
| Normalized Basic EPS | 1,018.81% | 460.84% | 554.55% | 33.18% | -439.36% |
| EPS Diluted | 992.89% | 159.26% | 102.39% | 101.34% | 92.56% |
| Normalized Diluted EPS | 948.65% | 448.40% | 520.45% | 19.73% | -450.53% |
| Average Basic Shares Outstanding | 1.51% | 1.42% | 6.76% | 22.67% | 44.32% |
| Average Diluted Shares Outstanding | 3.31% | 4.29% | 8.59% | 22.94% | 45.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |